Prescription CBD via Telehealth: A New Era Dawns as Rules Tighten

DENVER, CO – May 26, 2026 – A new chapter in the complex story of cannabis in America began today in Colorado. Watkins-based Kazmira Therapeutics has launched Cope Now, a first-of-its-kind telehealth platform dedicated to providing patients with prescription-only, pharmacy-compounded cannabidiol (CBD). The move signals a significant pivot away from the largely unregulated, consumer-driven CBD market toward a structured, medicalized framework, arriving just months before a federal crackdown is set to transform the industry.

Starting May 28, eligible patients in Colorado can schedule virtual consultations with licensed clinicians through the Cope Now platform. This initiative directly connects patients with medical professionals who can evaluate their needs and, when appropriate, prescribe personalized, pure CBD formulations free of tetrahydrocannabinol (THC), the psychoactive component of cannabis. The service aims to bridge a critical gap between the therapeutic promise of CBD and the often-confusing reality of the over-the-counter market.

A New Prescription for a Post-Loophole Market

The timing of the Cope Now launch is no coincidence. It is a direct response to a seismic shift in federal law. In November 2025, Congress passed H.R. 5371, legislation designed to close the so-called “hemp loophole” created by the 2018 Farm Bill. That loophole inadvertently paved the way for a multi-billion dollar market of intoxicating hemp-derived products like delta-8 THC, which were chemically similar to marijuana but technically legal.

With enforcement set to begin in November 2026, the new law will effectively dismantle this grey market. It redefines legal hemp by implementing a “total THC” standard, counting all psychoactive isomers, and sets a strict cap on THC content in finished products. Industry analysts predict this will render up to 95% of the current hemp-derived intoxicating products federally illegal, forcing a dramatic realignment of the cannabinoid industry.

It is within this new regulatory landscape that Kazmira Therapeutics is positioning its vertically integrated model—combining pharmaceutical-grade manufacturing, a compounding pharmacy, and now telehealth—as the new standard for compliance and patient care.

“The Cope Now platform provides a structured intake and evaluation process so care decisions are clinically driven, not consumer-directed,” said Kazmira Therapeutics co-founder and co-CEO Pulak Sharma in a statement. He emphasized the goal is to give patients a formal clinical pathway to ultra-pure compounded CBD that was previously unavailable.

Bridging the Gap Between Hype and Health

Beyond navigating regulatory changes, the new platform addresses a fundamental problem that has plagued the CBD market for years: the vast difference between what consumers typically use and what clinical research suggests is effective. A 2021 peer-reviewed study found that over half of active CBD users take less than 50 milligrams per day.

However, a growing body of scientific evidence indicates that to achieve therapeutic benefits for conditions like anxiety, much higher doses are required. Systematic reviews and clinical trials often point to a range of 200 to 400 milligrams per day, with some studies using up to 600 mg. This dosing discrepancy means many consumers may be experiencing little more than a placebo effect, undermining CBD's potential as a legitimate therapeutic agent.

Cope Now aims to solve this by creating a structured pathway to clinically effective dosing. After a telehealth consultation, prescriptions are sent to Kazmira Pharmacy, the nation's first 503A compounding pharmacy specializing in pure, THC-free CBD. Operating under these FDA regulations, the pharmacy can prepare individualized medications based on a clinician's specific prescription, a process distinct from mass-producing over-the-counter supplements.

The Clinical Engine: Telehealth and Expert Oversight

The platform's backbone is a partnership with Arora Health, a physician-led organization providing the clinical infrastructure and network of licensed prescribers. This ensures that every patient interaction is guided by medical expertise and adheres to strict compliance protocols. The patient journey is designed to be simple and secure: an initial eligibility screening, a one-on-one virtual consultation with a clinician, and if a prescription is issued, the compounded medication is delivered directly to the patient’s home.

This model leverages the convenience of telehealth to provide a level of care and product quality previously inaccessible to most. Dr. Sean Arora, co-founder and CEO of Arora Health and a prescribing physician on the platform, highlighted the importance of this structured approach.

“We believe physician-led cannabinoid care programs will become an important part of modern healthcare over the next decade,” Dr. Arora stated. “The key is ensuring these programs are built with the right guardrails: proper patient-provider relationships, robust intake and follow-up processes, clinical oversight, education, and ongoing compliance at every level.”

Colorado as a Proving Ground

Launching in Colorado provides Kazmira with a favorable environment to pilot its model. The state has a long history of progressive cannabis laws, including a mature regulatory framework for both medical and recreational use, and established rules permitting telehealth services. Colorado law already allows physicians to prescribe CBD for certain debilitating medical conditions, creating a clear legal pathway for Cope Now's operations.

While the platform is initially limited to Colorado, the company has announced plans for a multi-state expansion in the coming months. This expansion will undoubtedly face the challenge of navigating a patchwork of state-specific cannabis and telehealth regulations. However, by building a model grounded in federal pharmacy regulations and clinician-led care, Kazmira is betting that its compliant-first strategy will be the key to scalable success.

As the federal government prepares to close the book on the era of unregulated intoxicating hemp, platforms like Cope Now offer a glimpse into the future: a market where the therapeutic potential of cannabinoids is unlocked not through a retail shelf, but through a doctor’s prescription. For now, all eyes are on Colorado as it pioneers this new, highly regulated chapter in the story of American cannabis.